Topical preparations for skin hyperpigmentation

Taganov A.V.; Tamrazova O.B.; Sokolovskaya Yu.A.; Kozlova D.V.

doi:https://doi.org/10.17116/klinderma202322051632

Close metadata

Recommended articles:

Iatrogenic Hypermelanoses in a Doctor’s Practice. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):730-739

Assessment of Cream with Conjugated Hyaluronidase Effectiveness in the Correction of Post-Acne Syndrome. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):766-775

Experience of comprehensive treatment of erythematotelangiectatic rosacea. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):236-239

The role of azelaic acid in rosacea therapy. Russian Journal of Clinical Dermatology and Venereology. 2025;(3):349-357

Treatment of Reticular Veins with a Long-pulsed 1064 nm Nd:YAG Laser: a Pilot Study. Journal of Venous Disorders. 2025;(2):70-76

Risk Factors of Hyperpigmentation and Telangiectatic Matting Persistence after Sclerotherapy in C1 Patients. Journal of Venous Disorders. 2025;(2):77-82

Abstract:

Hyperpigmentation is a very common group of conditions with a pronounced negative impact on patients’ quality of life, that requires the necessity of development and search of effective and safe means to control it. Today, the market of depigmentary cosmetics is extremely various, and its global financial turnover continues to grow, that confirms the relevance of whitening products. The article presents the classification and review of modern preparations for hyperpigmentation treatment. The used drugs are divided into different classes depending on the mechanism of action. Conducted studies have shown that inhibitors of tyrosinase, a key enzyme in melanin synthesis, are the most effective group. Till recently, tyrosinase produced by mushrooms due to its commercial availability has been used for the synthesis and study of tyrosinase inhibitors in factories, so many of the released whitening agents are not clinically effective for control of hyperpigmentation in humans. It has been established that isobutylamido-thiazolyl-resorcinol has the most specific action for human’s tyrosinase. The molecule has a higher efficacy and better safety profile than other substances of the group, such as arbutin and hydroquinone, which were once the golden standard for skin hyperpigmentation treatment.

Keywords:

hyperpigmentation

melasma

lentigo

postinflammatory hyperpigmentation

postacne

tyrosinase inhibitors

arbutin

hydroquinone

kojic acid

nonanedioic acid

Authors:

Taganov A.V.

Peoples’ Friendship University of Russia

ORCID: 0000-0001-5056-374X

Tamrazova O.B.

Peoples’ Friendship University of Russia

ORCID: 0000-0003-3261-6718

Sokolovskaya Yu.A.

LLC Baiersdorf

ORCID: 0000-0003-3403-0841

Kozlova D.V.

Saint-Petersburg State Pediatric Medical University

ORCID: 0000-0002-6942-2880

Received:

16.08.2023

Accepted:

11.09.2023

Close metadata

References:

Rodionov AN, Zaslavsky DV, Sidikov AA. Klinicheskaya dermatologiya. Illustrirovannoe rukovodstvo dlya vrachej. 2nd ed.: M.: GEOTAR-media; 2019. (In Russ.).
Zaslavsky DV, Sidikov AA, Chuprov IN, et al. Fixed dischromical erythema. Dermatovenerologiya. Kosmetologiya. 2019;5(4):430-437. (In Russ.).
Hyperpigmentation Treatment Market Size, Share, Growth, And Industry Analysis By Type (Pharmacological Therapy, Laser Treatment, Chemical Peels and Bleach, Microdermabrasion, and Skin Grafting or Plastic Surgery) By Application (Skin Clinics, Drug and Cosmetic Stores, and Hypermarkets and Supermarkets), Regional Insights, and Forecast From 2023 To 2030. Accessed June 06, 2023. https://www.businessresearchinsights.com/market-reports/hyperpigmentation-treatment-market-102015
Lacz NL, Vafaie J, Kihiczak NI, Schwartz RA. Postinflammatory hyperpigmentation: a common but troubling condition. Int J Dermatol. 2004;43(5): 362-365. https://doi.org/10.1111/j.1365-4632.2004.02267.x
Nautiyal A, Wairkar S. Management of hyperpigmentation: Current treatments and emerging therapies. Pigment Cell Melanoma Res. 2021;34(6): 1000-1014. https://doi.org/10.1111/pcmr.12986
Zhu Y, Zeng X, Ying J, Cai Y, Qiu Y, Xiang W. Evaluating the quality of life among melasma patients using the MELASQoL scale: A systematic review and meta-analysis. PLoSONE. 2022;17(1):e0262833. https://doi.org/10.1371/journal.pone.0262833
Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res. 2018;31(4):461-465. https://doi.org/10.1111/pcmr.12684
Hyperpigmentation Treatment Devices Market Insights 2023 By Product Types, Application, and Major Key Players are covered in this 125 Pages Report By Precision Reports. Accessed June 06, 2023. https://www.precisionreports.co/enquiry/request-sample/21848012
Searle T, Al-Niaimi F, Ali FR. The top 10 cosmeceuticals for facial hyperpigmentation. Dermatol Ther. 2020;33(6):e14095. https://doi.org/10.1111/dth.14095
Tlostanova DZ, Masyukova SA, Ilina IV, Sokolovskaya YuA. Review of topical drugs for the correction of hyperpigmentations: comparative characteristics of thiamidol. Bulletin of the Medical Institute of Continuing Education. 2022; 4:30-36. https://doi.org/10.46393/27821714_2022_4_30
Bin B-H, Kim ST, Bhin J, Lee TR, Cho E-G. The Development of Sugar-Based Anti-Melanogenic Agents. Int J Mol Sci. 2016;17:583. https://doi.org/10.3390/ijms17040583
Bin B-H, Bhin J, Yang SH, Choi D-H, Park K, Shin DW, et al. Hyperosmotic Stress Reduces Melanin Production by Altering Melanosome Formation. PLoS ONE. 2014;9(8):e105965. https://doi.org/10.1371/journal.pone.0105965
Boissy RE, Visscher M, DeLong MA. DeoxyArbutin: A novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol. 2005;14:601-608. https://doi.org/10.1111/j.0906-6705.2005.00337.x
Anwar AI, Asmarani Y, Madjid A, Patellongi I, Adriani A, As’ad S, Kurniadi I. Comparison of 2% deoxyarbutin and 4% hydroquinone as a depigmenting agent in healthy individuals: A double-blind randomized controlled clinical trial. J Cosmet Dermatol. 2021;20(12):3953-3959. https://doi.org/10.1111/jocd.14050
Boo YC. Arbutin as a Skin Depigmenting Agent with Antimelanogenic and Antioxidant Properties. Antioxidants (Basel). 2021;10(7):1129. https://doi.org/10.3390/antiox10071129
Avonto C, Wang YH, Avula B, Wang M, Rua D, Khan IA. Comparative studies on the chemical and enzymatic stability of alpha- and beta-arbutin. Int J Cosmet Sci. 2016;38(2):187-193. https://doi.org/10.1111/ics.12275
Jeon JS, Kim BH, Lee SH, Kwon HJ, Bae HJ, Kim SK, Park JA, Shim JH, Abd El-Aty AM, Shin HC. Simultaneous determination of arbutin and its decomposed product hydroquinone in whitening creams using high-performance liquid chromatography with photodiode array detection: Effect of temperature and pH on decomposition. Int J Cosmet Sci. 2015;37(6):567-573. https://doi.org/10.1111/ics.12228
Bang SH, Han SJ, Kim DH. Hydrolysis of arbutin to hydroquinone by human skin bacteria and its effect on antioxidant activity. J CosmetDermatol. 2008;7(3):189-193. https://doi.org/10.1111/j.1473-2165.2008.00387.x
Chang NF, Chen YS, Lin YJ, Tai TH, Chen AN, Huang CH, Lin CC. Study of Hydroquinone Mediated Cytotoxicity and Hypopigmentation Effects from UVB-Irradiated Arbutin and DeoxyArbutin. Int J Mol Sci. 2017; 18(5):969. https://doi.org/10.3390/ijms18050969
Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther. 1996;276(2):765-769. PMID: 8632348.
Chakraborty AK, Funasaka Y, Komoto M, Ichihashi M. Effect of arbutin on melanogenic proteins in human melanocytes. Pigment Cell Res. 1998; 11:206-212. https://doi.org/10.1111/j.1600-0749.1998.tb00731.x
Inoue Y, Hasegawa S, Yamada T, Date Y, Mizutani H, Nakata S, Matsunaga K, Akamatsu H. Analysis of the effects of hydroquinone and arbutin on the differentiation of melanocytes. Biol Pharm Bull. 2013;36:1722-1730. https://doi.org/10.1248/bpb.b13-00206
Jiang L, Wang D, Zhang Y, Li J, Wu Z, Wang Z, Wang D. Investigation of the pro-apoptotic effects of arbutin and its acetylated derivative on murine melanoma cells. Int J Mol Med. 2018;41:1048-1054. https://doi.org/10.3892/ijmm.2017.3256
Greatens A, Hakozaki T, Koshoffer A, Epstein H, Schwemberger S, Babcock G, Bissett D, Takiwaki H, Arase S, Wickett RR, Boissy RE. Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp Dermatol. 2005;14(7):498-508. https://doi.org/10.1111/j.0906-6705.2005.00309.x
Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147(1):20-31. https://doi.org/10.1046/j.1365-2133.2002.04834.x
Chen HW, Chou YS, Young TH, Cheng NC. Inhibition of melanin synthesis and melanosome transfer by chitosan biomaterials. J Biomed Mater Res B Appl Biomater. 2020;108(4):1239-1250. https://doi.org/10.1002/jbm.b.34472
Ortonne JP. Retinoid therapy of pigmentary disorders. Dermatol Ther. 2006; 19(5):280-288. https://doi.org/10.1111/j.1529-8019.2006.00085.x
Leyden J, Wallo W. The mechanism of action and clinical benefits of soy for the treatment of hyperpigmentation. Int J Dermatol. 2011;50(4):470-477. https://doi.org/10.1111/j.1365-4632.2010.04765.x
Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res. 2003;16(2):101-110. https://doi.org/10.1034/j.1600-0749.2003.00029.x
Seiberg M, Paine C, Sharlow E, Costanzo M, Andrade-Gordon P, Eisinger M, Shapiro S. The proteasome-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interaction. Exp Cell Res. 2000;254:25-32. PMID: 10623462.
Seiberg M, Paine C, Sharlow E, Costanzo M, Andrade-Gordon P, Eisinger M, Shapiro SS. Inhibition of melanosome transfer results in skin lightening. J Invest Dermatol. 2000;115:162-167.
Lin CB, Chen N, Scarpa R, Guan F, Babiarz-Magee L, Liebel F, Li WH, Kizoulis M, Shapiro S, Seiberg M. LIGR, a protease-activated receptor-2-derived peptide, enhances skin pigmentation without inducing inflammatory processes. Pigment Cell Melanoma Res. 2008;21(2):172-183. https://doi.org/10.1111/j.1755-148X.2008.00441.x
Chaowattanapanit S, Silpa-Archa N, Kohli I, Lim HW, Hamzavi I. Postinflammatory hyperpigmentation: A comprehensive overview: Treatment options and prevention. J Am Acad Dermatol. 2017 Oct;77(4):607-621. PMID: 28917452. https://doi.org/10.1016/j.jaad.2017.01.036
Paine C, Sharlow E, Liebel F, et al. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol. 2001;116:587-595.
Hermanns JF, Petit L, Pierard-Franchimont C, et al. Assessment of topical hypopigmenting agents on solar lentigines of Asian women. Dermatology. 2002;204:281-286.
Kadekaro AL, Kavanagh R, Kanto H, Terzieva S, Hauser J, Kobayashi N, Schwemberger S, Cornelius J, Babcock G, Shertzer HG, Scott G, Abdel-Malek ZA. alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. CancerRes. 2005;65(10):4292-4299. https://doi.org/10.1158/0008-5472.CAN-04-4535
Gupta AK, Gover MD, Nouri K, et al. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048-1065.
Ebanks JP, Wickett RR, Boissy RE. Mechanisms regulating skin pigmentation: the rise and fall of complexion coloration. Int J Mol Sci. 2009;10(9): 4066-4087.
Xing X, Dan Y, Xu Z, Xiang L. Implications of Oxidative Stress in the Pathogenesis and Treatment of Hyperpigmentation Disorders. Oxid Med Cell Longev. 2022;2022:7881717. https://doi.org/10.1155/2022/7881717
Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013;169(3):41-56. https://doi.org/10.1111/bjd.12536
Breathnach A, Nazzaro-Porro M, Passi S, Zina G. Azelaic Acid Therapy in Disorders of Pigmentation. 1989;7(2):106-119. https://doi.org/10.1016/0738-081X(89)90061-8
Murashkin NN, Ivanov AM, Zaslavsky DV, Kamilova TA. Studies on effectiveness and safety of system retinoids use in therapy of adolescent acne. Vestnik dermatologii i venerologii. 2010;86(5):112-116. (In Russ.). https://doi.org/10.25208/vdv983
Zaslavsky DV, Egorova YuS, Olovyanishnikov OV, Volkova NS. To the question about history and complex therapy of rosacea. Russian Journal of Clinical Dermatology and Venereology = Klinichaskaya dermatologiya i venerologiya. 2009;7(3):80-84. (In Russ.).
Williamson T, Cameron J, McLeod K, Turner B, Quillen A, LaRose A, Lott J, Gaiser A. Concerns and Treatment Satisfaction in Patients Being Treated With Azelaic Acid Foam for Rosacea. J DrugsDermatol. 2019;18(4):381-386. PMID: 31013011.
Sung Hwan Woo, Jeung Suk Cho. Baek Seok Lee, Eun Ki Kim. Decolorization of melanin by lignin peroxidase from Phanerochaetechrysosporium. 2004;9(4):256-260. https://doi.org/10.1007/bf02942340
Falade Ayodeji O, Nwodo Uchechukwu U, Iweriebor Benson C, Green Ezekiel, Mabinya Leonard V, Okoh Anthony I. Lignin peroxidase functionalities and prospective applications. MicrobiologyOpen. 2016;6(1):e00394. https://doi.org/10.1002/mbo3.394
Zhong S-M, Sun N, Liu H-X, Niu Y-Q, Wu Y. Reduction of facial pigmentation of melasma by topical lignin peroxidase: A novel fast-acting skin-lightening agent. Exp Ther Med. 2015;9(2):341-344. https://doi.org/10.3892/etm.2014.2118
Yoshimura K, Tsukamoto K, Okazaki M, Virador VM, Lei TC, Suzuki Y, Uchida G, Kitano Y, Harii K. Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytes. J Dermatol Sci. 2001;27:68-75.
Ando H, Ryu A, Hashimoto A, Oka M, Ichashi M. Linoleic and a-linoleic acid lightens ultraviolet-induced hyperpigmentation of the skin. Arch Dermatol Res. 1998;290:375-381.
Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol. 2000;39:299-301
Smith W. The effects of topical L(+) lactic acid and ascorbic acid on skin withening. Int J Cosmetic Sci. 1999;21:33-40.
Yasumoto K, Yokoyama K, Takahashi K, et al. Functional analysis of microphtalmia-associated transcription factor in pigment cellspecific transcription of the human tyrosinase damily genes. J Biol Chem. 1997;272:503-509.
Tachibana M. MITF: a stream flowing for pigment cells. Pigment Cell Res. 2000;13:230-240.
Fang D, Tsuji Y, Setaluri V. Selective donw-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITF. NuclAcidsRes. 2002;30:3096-3106.
Watabe H, Soma Y, Ito M, Kawa Y, Mizoguchi M. All-transretinoic acid induces differentatiation and apoptosis of murine melanocyte precursors with induction of the microphtalmia-associated transcription factor. J Inv Dermatol. 2002;118:35-42.
Talwar HS, Griffiths EM, Fisher GJ, Russman A, Krach K, Benrazavi S, Voorhees JJ. Differential regulation of tyrosinase activity in skin of white and black individuals in vivo by topical retinoic acid. J Invest Dermatol. 1993; 100:800-805.
Rafal KS, Griffiths EM, Ditre CM, Finkel LJ, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) treatment for liver spot associted with photodamage. N Engl J Med. 1992;326:386-374.
Bulengo-Ransby SM, Griffiths EM, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328:1438-1443.
Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-348.
Chang T-S. An updated review of tyrosinase inhibitors. Int J Mol Sci. 2009;10: 2440-2475.
Fernandes MS, Kerkar S. Microorganisms as a source of tyrosinase inhibitors: a review. Ann Microbiol. 2017;67:343-358.
Zolghadri S, Bahrami A, Hassan Khan MT, Munoz-Munoz J, Garcia-Molina F, Garcia-Canovas F, Saboury AA. A comprehensive review on tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2019;34(1):279-309. https://doi.org/10.1080/14756366.2018.1545767
Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006;19(6):550-571. https://doi.org/10.1111/j.1600-0749.2006.00334.x
Fu B, Li H, Wang X, Lee FS and Cui S. Isolation andidentification of flavonoids in licorice and a study of their inhibi-tory effects on tyrosinase. J Agric Food Chem. 2005;53:7408-7414.
DeCaprio AP. The toxicology of hydroquinone--relevance to occupational and environmental exposure. Crit Rev Toxicol. 1999;29(3):283-330. https://doi.org/10.1080/10408449991349221
Espin JC, Varon R, Fenoll LG, Gilabert MA, Garcia-Ruiz PA, Tudela J, et al. Kinetic characterization of the substrate specificity and mechanism of mushroom tyrosinase. 2000;267:1270e9.
Pillaiyar T, Manickam M, Namasivayam V. Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2017;32(1):403-425. https://doi.org/10.1080/14756366.2016.1256882
Garcia-Molina F, Hiner AN, Fenoll LG, Rodriguez-Lopez JN, Garcia-Ruiz PA, Garcia-Canovas F, et al. Mushroom tyrosinase: catalase activity, inhibition, and suicide inactivation. J Agric Food Chem. 2005;53:3702e9.
Mann T, Gerwat W, Batzer J, Eggers K, Scherner C, Wenck H, Stäb F, Hearing VJ, Röhm KH, Kolbe L. Inhibition of Human Tyrosinase Requires Molecular Motifs Distinctively Different from Mushroom Tyrosinase. J Invest Dermatol. 2018;138(7):1601-1608. https://doi.org/10.1016/j.jid.2018.01.019
Philipp-Dormston WG, Vila Echagüe A, Pérez Damonte SH, Riedel J, Filbry A, Warnke K, Lofrano C, Roggenkamp D, Nippel G. Thiamidol containing treatment regimens in facial hyperpigmentation: An international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study. Int J Cosmet Sci. 2020;42(4):377-387. https://doi.org/10.1111/ics.12626
Lima PB, Dias JAF, Cassiano DP, Esposito ACC, Miot LDB, Bagatin E, Miot HA. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial. J Eur Acad Dermatol Venereol. 2021;35(9):1881-1887. https://doi.org/10.1111/jdv.17344
Roggenkamp D, Sammain A, Fürstenau M, Kausch M, Passeron T, Kolbe L. Thiamidol in moderate-to-severe melasma: 24-week, randomized, double-blind, vehicle-controlled clinical study with subsequent regression phase. J Dermatol. 2021;48(12):1871-1876. https://doi.org/10.1111/1346-8138.16080
Arrowitz C, Schoelermann AM, Mann T, Jiang LI, Weber T, Kolbe L. Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. J Invest Dermatol. 2019;139(8):1691-1698.e6. https://doi.org/10.1016/j.jid.2019.02.013
Vachiramon V, Kositkuljorn C, Leerunyakul K, Chanprapaph K. Isobutylamido thiazolyl resorcinol for prevention of UVB-induced hyperpigmentation. J CosmetDermatol. 2021;20(3):987-992. https://doi.org/10.1111/jocd.13615
Mann T, Arrowitz G, Gerwat W, et al. Isobutylamido-thiazolyl-resorcinol, a highly effective active for the treatment of facial hyperpigmentation. JournaloftheDermatologyNurses’ Association. 2020;12(2):EMBASE 634430634.